GIGABYTE
21.5.2024 03:01:30 CEST | Business Wire | Press release
GIGABYTE Technology, a leading IT innovator, is at the forefront of advancing global industries through cloud and AI computing systems, enhancing user experiences through hardware innovation. At COMPUTEX 2024, GIGABYTE unveils groundbreaking products poised to define the AI era.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240517872510/en/
GIGABYTE Showcases a Whole Lot of Computing Power at COMPUTEX, Taking the AI-driven New Evolution Head-On (Graphic: Business Wire)
Building on last year’s success, GIGABYTE looks to solidify its AI leadership with the theme “ACCEVOLUTION,” reflecting the increasing demand for computing and GIGABYTE’s ability to “accelerate the next evolution.” With its largest-ever presence at COMPUTEX, GIGABYTE’s booth stands as the largest single-brand exhibit. Showcasing a wide range of products, solutions, and applications aligned with the AI trend, GIGABYTE covers key tech trends including AI computing, advanced connectivity, future mobility, immersive reality, sustainability, and innovation.
GIGABYTE’s remarkable advancements in AI server development in recent years have garnered widespread attention, as GIGABYTE introduced the G593-SD0, the world’s first and only NVIDIA-certified 5U AI server to efficiently support the HGX™ H100 8 x SXM5. GIGABYTE further expands its super AI server lineup with ARM-based AI servers featuring the next-generation Grace Hopper™ superchip, and AI servers supporting AMD’s next-gen superchips MI300X GPU and MI300A APU. This year, on top of the upgraded H200 GPU, with NVIDIA unveiling the Blackwell architecture, GIGABYTE will showcase ahead of schedule at its booth the latest high-density servers compatible with GPUs such as B100 and B200. The highly-anticipated GB200 will also be demonstrated in a liquid-cooled cabinet as GB200 NVL72, acting as one massive GPU that can achieve 30 times the inference performance of the same amount of H100 GPUs. This allows visitors not only to witness these innovations firsthand but also to engage in discussions with professionals about the future of AI development and computing deployment.
As AI becomes ubiquitous, computing demand rises sharply in large data centers and AI startups. At this year’s COMPUTEX, GIGABYTE presents GIGA POD, a scalable rack integration solution, designed to meet data center-level deployments. Beyond showing GIGA POD’s comprehensive hardware and software integration and AI training optimization environments, on-site demonstrations will highlight its performance leadership and deployment flexibility.
GIGABYTE’s AI development encompasses GPU parallel computing, data storage, and network transmission in data centers. GIGABYTE’s R&D prowess is evident in industry-leading thermal and mechanical design, while modular design enables product diversity, speeding up time-to-market. At the booth, find servers for cloud to edge computing, high-performance to high-density storage, and computing options for SMBs and micro-enterprises, including DIY server motherboards tailored to AI development at various scales.
GIGABYTE’s green computing complements AI advancements perfectly. Innovations like Direct Liquid Cooling and Immersion Cooling redefine performance and efficiency, offering comprehensive setups for servers and cabinets. This enables servers with the latest chips from AMD, Intel, and NVIDIA to surpass traditional cooling limits, enhancing heat dissipation and computational density while ensuring stability. GIGABYTE’s sustainability commitment is evident in immersion cooling solutions, supporting technological advancements with optimal power usage.
GIGABYTE presents both robust AI model training capabilities and practical AI applications through industrial-grade embedded computers. Demonstrations span smart factories with AI-enabled machine vision and high-stability embedded computers for remote control, as well as retail bars utilizing panel PCs combined with AI recognition and big data analysis. Advancements in AI and next-generation CPU/GPU also bolster smart automotive applications, enhancing ADAS and in-vehicle Telematics devices.
In the consumer PC market, GIGABYTE leads with AI-enhanced products like motherboards, graphics cards, and AI gaming laptops. These feature stable AI computing power and innovative capabilities such as the AI Nexus in the AORUS 16X gaming laptop, offering applications like AI Power Gear and AI Boost. At our booth’s AI experience area, visitors can explore the latest AI applications and real-time interactions, including NVIDIA ACE and ChatRTX, delving immersively into cutting-edge AI technologies.
GIGABYTE is bringing an impressive products portfolio to COMPUTEX, demonstrating its capacity to accelerate the next evolution of technology in this changing AI landscape, and its abundance of computing solutions driven by the connectivity and velocity of data and AI can elevate businesses and empower individuals to thrive in the extra-fast growing and development time.
Visit GIGABYTE’s COMPUTEX event page.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240517872510/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom